Century Therapeutics Company Insiders
IPSC Stock | USD 1.30 0.09 7.44% |
Century Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Century Therapeutics suggests that all insiders are panicking. Century Therapeutics employs about 152 people. The company is managed by 17 executives with a total tenure of roughly 355 years, averaging almost 20.0 years of service per executive, having 8.94 employees per reported executive.
Century Therapeutics' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-11-04 | Douglas Carr | Disposed 283 @ 1.23 | View | ||
2024-08-05 | Douglas Carr | Disposed 289 @ 1.83 | View | ||
2024-07-26 | Gregory Russotti | Disposed 586 @ 2.5 | View | ||
2024-07-23 | Gregory Russotti | Disposed 200 @ 2.5 | View | ||
2024-06-20 | Gregory Russotti | Disposed 5000 @ 2.84 | View | ||
2024-06-05 | Gregory Russotti | Disposed 5000 @ 3 | View | ||
2024-05-06 | Gregory Russotti | Disposed 5000 @ 3.12 | View | ||
2024-05-03 | Douglas Carr | Disposed 257 @ 3.11 | View | ||
2024-04-22 | Gregory Russotti | Disposed 5000 @ 3.1 | View | ||
2024-03-07 | Adrienne Farid | Disposed 22831 @ 5.14 | View | ||
2024-02-05 | Douglas Carr | Disposed 643 @ 3.84 | View |
Monitoring Century Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Century |
Century Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.209) % which means that it has lost $0.209 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6261) %, meaning that it created substantial loss on money invested by shareholders. Century Therapeutics' management efficiency ratios could be used to measure how well Century Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.4. In addition to that, Return On Capital Employed is expected to decline to -0.45. At present, Century Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 195.3 M, whereas Total Assets are forecasted to decline to about 352.6 M.The current year's Common Stock Shares Outstanding is expected to grow to about 62 M, whereas Net Loss is forecasted to decline to (158.1 M).
Century Therapeutics Workforce Comparison
Century Therapeutics is rated second overall in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 651. Century Therapeutics totals roughly 152 in number of employees claiming about 23% of equities under Health Care industry.
Century Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Century Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Century Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Century Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pfeiffenberger Brent a day ago Acquisition by Pfeiffenberger Brent of 573691 shares of Century Therapeutics at 1.61 subject to Rule 16b-3 | ||
Carr Douglas over three weeks ago Disposition of 16611 shares by Carr Douglas of Century Therapeutics at 1.26 subject to Rule 16b-3 | ||
Morgan Conn over a month ago Insider Trading | ||
Luis Borges over a month ago Disposition of 7452 shares by Luis Borges of Century Therapeutics at 1.03 subject to Rule 16b-3 | ||
Chad Cowan over a month ago Insider Trading | ||
Quimi Daphne over two months ago Acquisition by Quimi Daphne of 5000 shares of Century Therapeutics at 1.5314 subject to Rule 16b-3 | ||
Carr Douglas over three months ago Disposition of 289 shares by Carr Douglas of Century Therapeutics at 1.827 subject to Rule 16b-3 | ||
Gregory Russotti over three months ago Disposition of 586 shares by Gregory Russotti of Century Therapeutics at 2.5 subject to Rule 16b-3 |
Century Therapeutics Notable Stakeholders
A Century Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Century Therapeutics often face trade-offs trying to please all of them. Century Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Century Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
PharmD MBA | CEO Director | Profile | |
Hyam MD | President Development | Profile | |
Adrienne Farid | COO Development | Profile | |
Katja Buhrer | Head SVP | Profile | |
Michael Diem | Chief Officer | Profile | |
Morgan Conn | Chief Officer | Profile | |
Michael Naso | Senior Engineering | Profile | |
Nick MD | Senior Development | Profile | |
Kenneth JD | Head Compliance | Profile | |
Chad Cowan | Chief Officer | Profile | |
Shane Williams | Chief Officer | Profile | |
Gregory Russotti | Chief Officer | Profile | |
Douglas CPA | Senior Secretary | Profile | |
Mark Wallet | Head VP | Profile | |
Luis Borges | Chief Officer | Profile | |
Michael MD | Chief Officer | Profile | |
Osvaldo Flores | CEO Pres | Profile |
About Century Therapeutics Management Performance
The success or failure of an entity such as Century Therapeutics often depends on how effective the management is. Century Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Century management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Century management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.38) | (0.40) | |
Return On Capital Employed | (0.43) | (0.45) | |
Return On Assets | (0.38) | (0.40) | |
Return On Equity | (0.74) | (0.70) |
Please note, the presentation of Century Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Century Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Century Therapeutics' management manipulating its earnings.
Century Therapeutics Workforce Analysis
Traditionally, organizations such as Century Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Century Therapeutics within its industry.Century Therapeutics Manpower Efficiency
Return on Century Therapeutics Manpower
Revenue Per Employee | 14.7K | |
Revenue Per Executive | 131.5K | |
Net Loss Per Employee | 899.2K | |
Net Loss Per Executive | 8M | |
Working Capital Per Employee | 1M | |
Working Capital Per Executive | 9.4M |
Complementary Tools for Century Stock analysis
When running Century Therapeutics' price analysis, check to measure Century Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Century Therapeutics is operating at the current time. Most of Century Therapeutics' value examination focuses on studying past and present price action to predict the probability of Century Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Century Therapeutics' price. Additionally, you may evaluate how the addition of Century Therapeutics to your portfolios can decrease your overall portfolio volatility.
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |